Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protara Therapeutics (TARA) Accounts Payables (2016 - 2026)

Protara Therapeutics' Accounts Payables history spans 14 years, with the latest figure at $4.0 million for Q1 2026.

  • Quarterly Accounts Payables rose 74.5% to $4.0 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $4.0 million through Mar 2026, up 74.5% year-over-year, with the annual reading at $3.5 million for FY2025, 21.7% down from the prior year.
  • Accounts Payables came in at $4.0 million for Q1 2026, up from $3.5 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $5.3 million in Q2 2025 to a low of $392000.0 in Q2 2022.
  • The 5-year median for Accounts Payables is $2.3 million (2025), against an average of $2.5 million.
  • Year-over-year, Accounts Payables skyrocketed 654.34% in 2023 and then tumbled 76.18% in 2024.
  • Protara Therapeutics' Accounts Payables stood at $1.6 million in 2022, then surged by 53.47% to $2.4 million in 2023, then surged by 81.96% to $4.4 million in 2024, then dropped by 21.7% to $3.5 million in 2025, then grew by 16.23% to $4.0 million in 2026.
  • Per Business Quant, the three most recent readings for TARA's Accounts Payables are $4.0 million (Q1 2026), $3.5 million (Q4 2025), and $4.5 million (Q3 2025).